Cytek Biosciences (NASDAQ:CTKB) Sets New 52-Week High - What's Next?

Cytek Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Cytek Biosciences reached a 52-week high of $6.37 on Friday, before trading at $6.225; its 50-day and 200-day moving averages were $5.60 and $4.70, respectively.
  • Quarterly results modestly beat expectations: EPS was a loss of $0.05 versus the expected loss of $0.07, while revenue of $53.23 million topped estimates of $53.05 million.
  • Analyst views were mixed, with a consensus “Hold” rating and a $5.67 price target; Stephens raised its target to $7, while institutional investors and hedge funds held 69.46% of the shares.
  • Five stocks we like better than Cytek Biosciences.

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report)'s stock price reached a new 52-week high on Friday. The stock traded as high as $6.37 and last traded at $6.2250, with a volume of 197,077 shares changing hands. The stock had previously closed at $6.32.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Cytek Biosciences from a "hold" rating to a "buy" rating in a research report on Saturday, November 7th. Morgan Stanley set a $5.00 price target on shares of Cytek Biosciences in a report on Friday, August 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cytek Biosciences in a research note on Monday, September 21st. Finally, Stephens increased their price objective on shares of Cytek Biosciences from $6.00 to $7.00 and gave the company an "overweight" rating in a report on Tuesday, November 10th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Cytek Biosciences presently has an average rating of "Hold" and a consensus price target of $5.67.

Check Out Our Latest Stock Report on CTKB

Cytek Biosciences Trading Down 1.3%

The business's fifty day moving average price is $5.60 and its 200 day moving average price is $4.70. The firm has a market capitalization of $816.07 million, a price-to-earnings ratio of -9.90 and a beta of 1.15.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. Cytek Biosciences had a negative return on equity of 13.13% and a negative net margin of 39.10%. The business had revenue of $53.23 million during the quarter, compared to analysts' expectations of $53.05 million. As a group, sell-side analysts forecast that Cytek Biosciences, Inc. will post -0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytek Biosciences

Institutional investors have recently made changes to their positions in the stock. Algert Global LLC lifted its holdings in shares of Cytek Biosciences by 1,122.6% during the 3rd quarter. Algert Global LLC now owns 182,100 shares of the company's stock worth $1,085,000 after acquiring an additional 167,205 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Cytek Biosciences by 7.2% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,323,524 shares of the company's stock valued at $13,848,000 after acquiring an additional 156,009 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Cytek Biosciences by 60.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,428,747 shares of the company's stock valued at $14,475,000 after acquiring an additional 917,432 shares in the last quarter. CenterBook Partners LP boosted its position in Cytek Biosciences by 16.0% during the 3rd quarter. CenterBook Partners LP now owns 173,020 shares of the company's stock worth $1,031,000 after purchasing an additional 23,840 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in shares of Cytek Biosciences by 227.2% during the 2nd quarter. Squarepoint Ops LLC now owns 82,776 shares of the company's stock valued at $367,000 after buying an additional 57,480 shares during the period. 69.46% of the stock is owned by institutional investors and hedge funds.

About Cytek Biosciences

(Get Free Report)

Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company's product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cytek Biosciences Right Now?

Before you consider Cytek Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.

While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines